Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Progen receives provisional approval to undertake clinical studies of PI-88 at second site

Sep. 1, 1999

DuPont team presents new cdk inhibitors at ACS meeting

Aug. 31, 1999

Celecoxib NDA receives priority review designation for FAP

Aug. 31, 1999

Searle pays milestone to Epimmune for anticancer candidate

Aug. 31, 1999

LB-42908 inhibits protein farnesyltransferase in vitro, in vivo

Aug. 30, 1999

Preclinical studies of abetafen show potential for treatment of prostate disease

Aug. 30, 1999

Cytotoxic macrolide compounds HA-1 and TH-2 obtained from marine sources

Aug. 30, 1999

NaPro BioTherapeutics focuses on new anticancer programs

Aug. 30, 1999

NuOncology Labs awarded second U.S. patent

Aug. 30, 1999

Evacet/Taxol combination enters advanced breast cancer trials

Aug. 30, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...